Export momentum and margin resilience — set against monsoon seasonality
Sumitomo Chemical India reports Q2 FY2027 results on October 26. After a strong Q1 (+20% net profit on operational gains plus a one-off insurance claim), the Street expects sustained revenue and profit growth as the agricultural sector stabilises and exports accelerate. The key — tracking whether margin gains persist and export mix offset domestic weather volatility.
The Setup
Sumitomo Chemical India is expected to report Q2 FY2027 results on October 26, 2026. The company enters the quarter on the back of a strong Q1 (revenue ₹1,054 Cr, net profit ₹216.5 Cr), though that profit included a ₹26.9 Cr non-recurring insurance claim for business interruption from a 2023 fire incident. Stripping that out, underlying operational profit momentum remains solid — and the Street expects that momentum to sustain. The real question for Q2: whether export growth (which jumped +26% YoY in Q1, now 16% of total revenue) can offset the seasonal pressure from monsoon-dependent domestic demand.
~₹850–900 Cr
Full-year FY27 consensus ₹3,580 Cr; Q1 was ₹1,054 Cr; quarterly run-rate suggests ~₹850 Cr midpoint. Q2 FY26 was ₹930 Cr (easier comp)
20–22%
Q1 margin 21.9% (up 120 bps YoY) on pricing actions and favorable product mix. Watch for continuation amid commodity normalization
₹180–200 Cr
Q1 underlying PAT ~₹190 Cr (ex-insurance claim). Growth sustained from operational leverage and export mix
+26% YoY (Q1)
Now 16% of total revenue vs 13% prior year. International scale-up offsetting domestic weakness — monitor new product contribution
A strong Q2 print would show: revenue holding at ₹900+ Cr (flat/up vs Q1 run-rate), EBITDA margin holding above 21%, and PAT in the ₹190–210 Cr range — confirming that pricing power, export gains, and operational discipline are sustaining margin expansion. A weak print would reveal: revenue slipping below ₹800 Cr, margin compression below 20%, or profit decline — signaling either domestic demand collapse or pricing pressure returning. The Street's baseline is neither: orderly quarterly performance within FY27 guidance range.
Is the Company on Track?
For FY2027, consensus calls for ₹3,580 Cr revenue (+5.7% YoY) and EPS ₹12.60 (+12.5%). The company does not appear to have issued formal quarterly or full-year guidance; judgement relies on the Q1 print and sector trajectory. Q1's combination of flat sequential revenue (from a seasonally weak Q4) plus strong EBITDA and profit suggests the company is tracking the full-year plan. The path requires Q2–Q4 to deliver at run-rate: six quarters at ~₹840 Cr revenue (Q1 ₹1,054 Cr outlier, four normalized quarters at ~₹840 Cr, one seasonal quarter) would land in the ₹3,500–3,600 Cr band. The agrochemical sector's transition from destocking to normalization supports this. The swing factor: how quickly domestic agriculture revives post-monsoon (Rabi season) and whether new product launches (flagged in annual reports but not yet quantified) contribute.
What the Street Says
What's Happened Since Q1
No material operational announcements since the July 27, 2026 Q1 results release. The company announced a board meeting for October 26 to approve Q2 results (routine). A director (Ninad D. Gupte, Non-Executive, Non-Independent) resigned effective August 31 — non-material. The annual report (July 2026) flagged 'multiple growth avenues' and new product launches for 2026–27, consistent with the export momentum and mix gain narrative, but no specific launch dates or revenue impact have been disclosed. FY26 annual revenue was ₹31.9 Bn (rounded ₹3,190 Cr) in a year marked by climate challenges and commodity pressure, so FY27's implied +5.7% growth represents a modest but credible recovery.
The Watch List
1 · Revenue vs. ₹850–900 Cr expectation
Does domestic weakness persist, or is the Rabi season/post-monsoon recovery gaining traction? A print below ₹800 Cr or above ₹950 Cr would signal a significant divergence from FY27 run-rate and force guidance revision odds.
2 · Underlying PAT (backing out one-offs)
Q1 had ₹26.9 Cr insurance claim. Confirm that recurring PAT (ex-claim) was ~₹190 Cr and is sustained or higher in Q2. This reveals whether operational leverage and margin gains are real or if Q1 was a peak.
3 · Export contribution and new product uptake
Export revenue grew +26% YoY in Q1 (16% of total). In Q2, watch the commentary on new launches, international expansion plans, and whether export margin is sustained (exports often carry lower gross margin). This is the margin narrative's anchor.
Sumitomo Chemical India is tracking FY2027 guidance on the back of agrochemical sector stabilization, margin expansion, and export acceleration. Q2, seasonally a tougher quarter for agriculture-linked demand, will test whether those gains are real or Q1 was a peak. The stock trades at a 45% discount to analyst target price and is deeply oversold (RSI 23), yet the Street remains consistently bullish — a disconnect worth watching. The result on October 26 will clarify whether the consensus 'Buy' case (margin resilience, export momentum, sector recovery) is validated or whether the market's skepticism is justified.